Research and development has been the foundation for the success of Boehringer Ingelheim and continues to be the major driver of innovative, new medicines for the treatment of diseases with an unmet therapeutic need. The company focuses on four therapeutic research areas with high unmet medical need: immunology & respiratory diseases, cardiometabolic diseases, central nervous system diseases, and oncology.
Boehringer Ingelheim in Oncology
The ‘Let’s Work’ initiative launched by Boehringer Ingelheim in Oncology is the guiding ethos directing the company’s commitment to oncology and to improving the future of cancer patients. This principle recognises that collaboration is fundamental to making a difference to patients’ lives. Working together connects, potentiates and enhances ideas, research and education. “Let’s Learn”, an extension of this initiative, is an invitation to all healthcare professionals working in oncology to share experiences, exchange ideas, and learn together, in order to advance the common goal of improving the outlook for cancer patients. A central aim of Boehringer Ingelheim is to strengthen the dialog between healthcare professionals in oncology. Against this backdrop, Boehringer Ingelheim are proud to support ESMO through ePatCare, an educational software tool for presenting interactive patient cases and creating patient case libraries at an individual-user as well as an institutional level.
Educational e-tool and content provided by this sponsor: an innovative app to share your individual oncology patient cases with your colleagues
ePatCare® is a software tool for creating, viewing and sharing clinical patient cases within the Oncology Community. It enables oncologists to easily transfer their individual cases into a predefined and attractive format for presentation and storage, but crucially, it can also be scaled up to facilitate the sharing of expertise and know how across a larger community. Owing to the built-in interactive features, ePatCare cases lend themselves perfectly to interactive presentations and use as teaching aids. Through the ESMO ePatCare app, developed especially for ESMO, you can view, share and contribute to an expanding platform of patient cases and thus both benefit from and support the accrual of clinical knowledge for the purpose of mutual education and the potential of ultimately improving patient management.
ePatCare® was announced Best App winner at the PM360 Trailblazer awards 2013, and was awarded silver at the 2014 e-learning awards in London, UK, in the category Most Innovative New Learning Product.
Download the free iOS and Android app
Find out more about the ESMO Patient Case Library and view the latest ePatCare® patient case created in collaboration with Boehringer Ingelheim.
Boehringer Ingelheim is pleased to bring further select medical education resources to the attention of ESMO OncologyPRO users.
ePatCare case studies
Choose from three exciting ePatCare oncology case studies to view and download.
- Lung cancer in a former half-marathon runner
- Progressive cough in an elderly never-smoker
- MDS diagnosis after presentation with dyspnea
Educational cancer slide kits
Boehringer Ingelheim offers slide kits suitable as teaching and learning aids for reviewing the fundamentals of cancer. The NSCLC slide KIT outlines the epidemiology, pathology, clinical features, and risk factors of the disease.
Visit one of our virtual symposia and stay up-to-date with the experts’ points of view, for example in lung cancer.
Access further related items on NSCLC new:
- Access Boehringer Ingelheim materials from the ESMO Asia 2016 congress here, including a recording from the satellite symposium that was sponsored by Boehringer Ingelheim, entitled “Insights and perspectives in non-small cell lung cancer treatment”.
- Boehringer Ingelheim supports the Springer “memo inOncology SPECIAL ISSUE” congress report series with an unrestricted grant. Each issue summarises the latest findings in lung cancer to come out of a major international congress. Read an article on recent advances in anti-EGFR therapy here.
The European Society for Medical Oncology (ESMO) wishes to thank Boehringer Ingelheim for making this content available.
ESMO only accepts content from third parties after careful evaluation of its educational and scientific relevance to the ESMO target audience. Eligible material should meet the essential criterion of non-promotional intent. Such material may be published in other resources, but the content donor has given permission to ESMO for use in OncologyPRO.